January 18, 2018, 4:11 am
Facebook iconTwitter iconYouTube iconGoogle+ icon
1 Philippine Peso = 0.07263 UAE Dirham
1 Philippine Peso = 2.14992 Albanian Lek
1 Philippine Peso = 0.03521 Neth Antilles Guilder
1 Philippine Peso = 0.37318 Argentine Peso
1 Philippine Peso = 0.02474 Australian Dollar
1 Philippine Peso = 0.03521 Aruba Florin
1 Philippine Peso = 0.03956 Barbados Dollar
1 Philippine Peso = 1.63687 Bangladesh Taka
1 Philippine Peso = 0.03163 Bulgarian Lev
1 Philippine Peso = 0.00745 Bahraini Dinar
1 Philippine Peso = 34.63172 Burundi Franc
1 Philippine Peso = 0.01978 Bermuda Dollar
1 Philippine Peso = 0.02627 Brunei Dollar
1 Philippine Peso = 0.13568 Bolivian Boliviano
1 Philippine Peso = 0.06382 Brazilian Real
1 Philippine Peso = 0.01978 Bahamian Dollar
1 Philippine Peso = 1.25445 Bhutan Ngultrum
1 Philippine Peso = 0.19324 Botswana Pula
1 Philippine Peso = 395.96518 Belarus Ruble
1 Philippine Peso = 0.03951 Belize Dollar
1 Philippine Peso = 0.02456 Canadian Dollar
1 Philippine Peso = 0.01896 Swiss Franc
1 Philippine Peso = 11.96895 Chilean Peso
1 Philippine Peso = 0.12736 Chinese Yuan
1 Philippine Peso = 56.62579 Colombian Peso
1 Philippine Peso = 11.15506 Costa Rica Colon
1 Philippine Peso = 0.01978 Cuban Peso
1 Philippine Peso = 1.77275 Cape Verde Escudo
1 Philippine Peso = 0.40883 Czech Koruna
1 Philippine Peso = 3.49743 Djibouti Franc
1 Philippine Peso = 0.1197 Danish Krone
1 Philippine Peso = 0.95886 Dominican Peso
1 Philippine Peso = 2.24462 Algerian Dinar
1 Philippine Peso = 0.25141 Estonian Kroon
1 Philippine Peso = 0.34978 Egyptian Pound
1 Philippine Peso = 0.53817 Ethiopian Birr
1 Philippine Peso = 0.01607 Euro
1 Philippine Peso = 0.03956 Fiji Dollar
1 Philippine Peso = 0.01433 Falkland Islands Pound
1 Philippine Peso = 0.01431 British Pound
1 Philippine Peso = 0.08957 Ghanaian Cedi
1 Philippine Peso = 0.9371 Gambian Dalasi
1 Philippine Peso = 177.94699 Guinea Franc
1 Philippine Peso = 0.14509 Guatemala Quetzal
1 Philippine Peso = 4.07219 Guyana Dollar
1 Philippine Peso = 0.15475 Hong Kong Dollar
1 Philippine Peso = 0.46509 Honduras Lempira
1 Philippine Peso = 0.11922 Croatian Kuna
1 Philippine Peso = 1.25771 Haiti Gourde
1 Philippine Peso = 4.9644 Hungarian Forint
1 Philippine Peso = 263.35047 Indonesian Rupiah
1 Philippine Peso = 0.06775 Israeli Shekel
1 Philippine Peso = 1.266 Indian Rupee
1 Philippine Peso = 23.41772 Iraqi Dinar
1 Philippine Peso = 723.08147 Iran Rial
1 Philippine Peso = 2.02255 Iceland Krona
1 Philippine Peso = 2.43928 Jamaican Dollar
1 Philippine Peso = 0.01399 Jordanian Dinar
1 Philippine Peso = 2.18216 Japanese Yen
1 Philippine Peso = 2.03224 Kenyan Shilling
1 Philippine Peso = 1.37189 Kyrgyzstan Som
1 Philippine Peso = 79.26622 Cambodia Riel
1 Philippine Peso = 8.12896 Comoros Franc
1 Philippine Peso = 17.80063 North Korean Won
1 Philippine Peso = 21.02452 Korean Won
1 Philippine Peso = 0.00594 Kuwaiti Dinar
1 Philippine Peso = 0.01622 Cayman Islands Dollar
1 Philippine Peso = 6.47765 Kazakhstan Tenge
1 Philippine Peso = 163.7856 Lao Kip
1 Philippine Peso = 29.88528 Lebanese Pound
1 Philippine Peso = 3.04292 Sri Lanka Rupee
1 Philippine Peso = 2.5093 Liberian Dollar
1 Philippine Peso = 0.24248 Lesotho Loti
1 Philippine Peso = 0.0603 Lithuanian Lita
1 Philippine Peso = 0.01227 Latvian Lat
1 Philippine Peso = 0.02646 Libyan Dinar
1 Philippine Peso = 0.18183 Moroccan Dirham
1 Philippine Peso = 0.33356 Moldovan Leu
1 Philippine Peso = 0.98418 Macedonian Denar
1 Philippine Peso = 26.46361 Myanmar Kyat
1 Philippine Peso = 47.8837 Mongolian Tugrik
1 Philippine Peso = 0.1593 Macau Pataca
1 Philippine Peso = 6.96203 Mauritania Ougulya
1 Philippine Peso = 0.64676 Mauritius Rupee
1 Philippine Peso = 0.30795 Maldives Rufiyaa
1 Philippine Peso = 14.11195 Malawi Kwacha
1 Philippine Peso = 0.37086 Mexican Peso
1 Philippine Peso = 0.07803 Malaysian Ringgit
1 Philippine Peso = 0.24161 Namibian Dollar
1 Philippine Peso = 7.0807 Nigerian Naira
1 Philippine Peso = 0.6072 Nicaragua Cordoba
1 Philippine Peso = 0.15518 Norwegian Krone
1 Philippine Peso = 2.0265 Nepalese Rupee
1 Philippine Peso = 0.02715 New Zealand Dollar
1 Philippine Peso = 0.0076 Omani Rial
1 Philippine Peso = 0.01978 Panama Balboa
1 Philippine Peso = 0.06341 Peruvian Nuevo Sol
1 Philippine Peso = 0.0624 Papua New Guinea Kina
1 Philippine Peso = 1 Philippine Peso
1 Philippine Peso = 2.18473 Pakistani Rupee
1 Philippine Peso = 0.06706 Polish Zloty
1 Philippine Peso = 110.52215 Paraguayan Guarani
1 Philippine Peso = 0.07202 Qatar Rial
1 Philippine Peso = 0.07488 Romanian New Leu
1 Philippine Peso = 1.11739 Russian Rouble
1 Philippine Peso = 16.52987 Rwanda Franc
1 Philippine Peso = 0.07417 Saudi Arabian Riyal
1 Philippine Peso = 0.15387 Solomon Islands Dollar
1 Philippine Peso = 0.26503 Seychelles Rupee
1 Philippine Peso = 0.13841 Sudanese Pound
1 Philippine Peso = 0.15847 Swedish Krona
1 Philippine Peso = 0.02609 Singapore Dollar
1 Philippine Peso = 0.01433 St Helena Pound
1 Philippine Peso = 0.4392 Slovak Koruna
1 Philippine Peso = 150.90981 Sierra Leone Leone
1 Philippine Peso = 10.85839 Somali Shilling
1 Philippine Peso = 393.89636 Sao Tome Dobra
1 Philippine Peso = 0.17306 El Salvador Colon
1 Philippine Peso = 10.18552 Syrian Pound
1 Philippine Peso = 0.24175 Swaziland Lilageni
1 Philippine Peso = 0.63054 Thai Baht
1 Philippine Peso = 0.04769 Tunisian Dinar
1 Philippine Peso = 0.04409 Tongan paʻanga
1 Philippine Peso = 0.07507 Turkish Lira
1 Philippine Peso = 0.13281 Trinidad Tobago Dollar
1 Philippine Peso = 0.5839 Taiwan Dollar
1 Philippine Peso = 44.34335 Tanzanian Shilling
1 Philippine Peso = 0.56547 Ukraine Hryvnia
1 Philippine Peso = 71.79588 Ugandan Shilling
1 Philippine Peso = 0.01978 United States Dollar
1 Philippine Peso = 0.56468 Uruguayan New Peso
1 Philippine Peso = 160.81883 Uzbekistan Sum
1 Philippine Peso = 0.19729 Venezuelan Bolivar
1 Philippine Peso = 449.14952 Vietnam Dong
1 Philippine Peso = 2.0449 Vanuatu Vatu
1 Philippine Peso = 0.04966 Samoa Tala
1 Philippine Peso = 10.5352 CFA Franc (BEAC)
1 Philippine Peso = 0.0534 East Caribbean Dollar
1 Philippine Peso = 10.5352 CFA Franc (BCEAO)
1 Philippine Peso = 1.90645 Pacific Franc
1 Philippine Peso = 4.94363 Yemen Riyal
1 Philippine Peso = 0.24183 South African Rand
1 Philippine Peso = 102.64043 Zambian Kwacha
1 Philippine Peso = 7.15783 Zimbabwe dollar

PH defied experts’ advice in pursuing vaccine program

AS she announced in January 2016 that the Philippines would immunize one million children with a new dengue vaccine, the nation’s then health secretary Janette Garin boasted it was a world-first and a tribute to her country’s “expertise” in research.

At the time, it seemed the Philippines could be on the cusp of a breakthrough to combat a potentially lethal tropical virus that had been endemic in large parts of the Southeast Asian nation for decades.

Almost two years later, the program lies in tatters and has been suspended after Sanofi Pasteur, a division of French drug firm Sanofi, said at the end of last month the vaccine itself may in some cases increase the risk of severe dengue in recipients not previously infected by the virus.

Documents reviewed by Reuters that have not been disclosed until now, as well as interviews with local experts, show that key recommendations made by a Department of Health (DOH) advisory body of doctors and pharmacologists were not heeded before the program was rolled out to 830,000 children.

After Garin’s announcement, the Formulary Executive Council (FEC) of advisers urged caution over the vaccine because it said its safety and cost-effectiveness had not been established.

After twice meeting in January, the panel approved the state’s purchase of the vaccine on Feb. 1, 2016 but recommended stringent conditions, minutes of all three meetings show.

“Based on the available scientific evidence presented to the Council, there is still a need to establish long-term safety, effectiveness and cost-effectiveness,” the FEC told Garin in a letter on that day. The letter was reviewed by Reuters.

The FEC said Dengvaxia should be introduced through small-scale pilot tests and phased implementation rather than across three regions in the country at the same time, and only after a detailed “baseline” study of the prevalence and strains of dengue in the targeted area, the FEC letter and minutes of the meetings said.

The experts also recommended that Dengvaxia be bought in small batches so the price could be negotiated down. An economic evaluation report commissioned by Garin’s own department had found the proposed cost of P1,000 ($21.29) per dose was “not cost-effective” from a public payer perspective, the minutes from the meetings reveal.

For reasons that Reuters was unable to determine, these recommendations were ignored.

‘VERY ANGRY’

The DOH purchased 3 million doses of Dengvaxia in one lot, enough for the required three vaccinations for each child in the proposed immunization program and paid P1,000 per dose, a copy of the purchase order reviewed by Reuters shows.

It conducted a “limited baseline study” in late February and March 2016, but the survey looked at “common illnesses” rather than the prevalence of dengue, according to guidelines issued by Garin’s office at the time and reviewed by Reuters.

Garin, who was part of the government of former president Benigno Aquino and was replaced when President Duterte took power in June 2016, did not respond to requests for comment on why she ignored the local experts’ recommendations.

A physician, Garin has defended her conduct and a program that she said was “implemented in accordance with WHO guidance and recommendations”.

“I understand the concern,” she told ABS-CBN on Friday. “Even us, we’re also very angry when we learned about Sanofi’s announcement about severe dengue. I’m also a mother. My child was also vaccinated. I was also vaccinated.”

DOH spokesman Lyndon Lee Suy also did not respond to text messages or questions emailed to him.

Sanofi Philippines declined comment on the Philippines government decision. However, Dr. Su-Peing Ng, Global Medical Head of Sanofi Pasteur, told Reuters: “We communicated all known benefits and risks of the vaccine to the Philippine government.”

Rontgene Solante, former president of the Philippines Society for Microbiology and Infectious Diseases, said health officials were motivated to end the debilitating impact of dengue on the Philippines, where there are about 200,000 reported cases each year and many more unreported.

Over 1,000 people died of the disease in the country last year.

Two months after the FEC wrote to the health secretary, the DOH began immunizing one million students around the age of 10 in all three target areas in April 2016, in accordance with its original plan but at odds with the FEC’s recommendations to conduct a slow roll-out of the vaccine.

“The usual process for the DOH that has protected our children for so many decades was not followed. That’s a fact,” said Susan Mercado, a former health undersecretary and former senior official at the World Health Organization (WHO).

WHO said in April 2016 that the Philippines’ campaign appeared to meet its criteria for using Dengvaxia because the targeted regions had high levels of dengue exposure; the vaccine would be provided to children 9 years and older; and they would each receive three doses.

WHO was not involved in the deliberations of the FEC, according to the minutes. It said in a statement last week that a position paper on the dengue vaccine it published in July 2016 did not include a recommendation for countries to introduce it.

Now, after Sanofi’s warnings, WHO has said it agrees with the government’s decision to suspend the immunization program.

DON’T IGNORE EXPERTISE

The current secretary of health in the Duterte administration, Francisco Duque III, said he would carry out a “thorough analysis” of the FEC’s recommendations and the program before passing judgment. He said the Council’s recommendations were not legally enforceable.

“At the end of the day, the final decision is made by (the) secretary of health,” he told Reuters. “But because of the expertise that the members of the FEC have, it is something that you don’t want to ignore.”

Underpinning the concerns in 2016 about Dengvaxia, since confirmed by Sanofi, were fears that the vaccine would act like a primary infection for those who had never had dengue.

If they were bitten by a mosquito carrying the virus after the vaccination, it could be akin to getting dengue a second time, which often leads to far more severe symptoms and potentially death if bad cases are not treated quickly.

The concerns were first raised by noted U.S.-based tropical disease expert, Dr. Scott Halstead, who urged both Sanofi and the WHO to proceed with caution.

In the Philippines, Dr. Antonio Dans, an epidemiologist from the University of the Philippines, led a delegation of physicians to the DOH in March 2016 where, citing Halstead’s research, they pressed for the campaign to be aborted.

“The data was not definitive but it was clear there were uncertainties and risks. Why not wait for the complete studies to be finished before endangering so many children?” Dans told Reuters.

In a Senate hearing late last year, Garin said she was aware of Halstead’s assessment but dismissed it. “This is a theory ... it has not been proven,” she said at the time.

Two sources involved in the program said no antibody testing was undertaken, as recommended by the FEC.

Antibody testing, while not 100 percent accurate, indicates whether an individual has had dengue before.

Duque is demanding that Sanofi Pasteur refund the P3 billion ($60 million) paid for the vaccinations, and has threatened legal action against Sanofi if it is proven to have withheld information.

Duque told Reuters he was concerned that the program was paid from an “off-budget” allocation, meaning it bypassed congressional scrutiny. Reuters was unable to confirm this. - Reuters
Category: 
Rating: 
No votes yet

Column of the Day

From the forge of Vulkanus

By BERNARD KARGANILLA | January 18,2018
‘Woe unto you, ye sons of pain that are this day in earth – C. S. Lewis [Ode for New Year’s Day]’

Opinion of the Day

Sudden cardiac death

By PHILIP S. CHUA | January 18, 2018
‘Even a single coronary blockage, if severe enough, could be dangerous, and deadly, depending on the portion of the heart that suffers.’